Nanoparticle-based Drug Delivery System for Post Myocardial Infarction Management

Abstract

Review Nanoparticle-based Drug Delivery System for Post Myocardial Infarction Management Minxuan Liu, Chiara Ramponi, Xiaoxue Fan, Xinzhuang Zhang, Liang Cao, Zhenzhong Wang, and Wei Xiao * State Key Laboratory of New-tech for Chinese Medicine Pharmaceutical Process, Jiangsu Kanion Pharmaceutical Co., Ltd., Lianyungang, 222001, China. * Correspondence: xw_kanion@163.com Received: 15 October 2022 Accepted: 2 November 2022 Published: 21 December 2022 Abstract: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the world. Myocardial infraction (MI) as one of the most harmful forms of ischaemic heart disease requires rigorous and tempestive approaches which are not met by current clinical interventions. Nanotechnology has developed promising clinical applications for imaging, diagnostic, gene delivery and tissue engineering, which makes this technology a potential candidate for novel therapeutic delivery approach. This review highlights several recent research reports regarding advances in drug delivery using nanoparticle-based (NP) strategies, as well as future challenges and opportunities.

Recent Advances in Natural Plant-based Treatment of Myocardial Ischemia-reperfusion Injury

“…Due to the lack of research on the active ingredients of NPPs, and the shortcomings in bioavailability and affinity of the active ingredients, the therapeutic effect of NPPs administration is slow [174]. Changing the dosage form of drugs may be necessary to achieve and maintain an effective blood concentration for therapeutic purposes [175].…”

“…There are some shortcomings in the safety of NPPs in clinical application, including the following aspects: the mechanism of action of NPPs is complex; the active ingredients are difficult to determine; the dose and frequency of use are difficult to control; it may have poor efficacy or excessive reactions. In addition, the drug utilization of NPPs is generally low, thus larger doses and longer administration cycles are required, and this may cause toxic reactions[175]. There are many interactions and interference factors between NPPs and other therapeutic drugs, which need to be evaluated and controlled in detail, according to the physiological characteristics and conditions of specific patients.Future research on the use of NPP for treatment of MIRI needs to further explore NPPs' anti-MIRI mechanism and the structure-activity relationship of NPPs.…”

Current Progress in Drug Target Identification and Drug Delivery

“…Moreover, the encapsulation or conjunction of NPs with peptides, antibodies or small molecules can further enhance compound solubility, reduce toxicity, and improve chemical stability in the circulation. Xiao et al from Kanion Pharmaceutical Co present 3 novel NP-based drug delivery systems tested in myocardial infarction condition, such as enzymeresponsive NPs, magnetic antibody-linked NPs, and extracellular vehicles (EVs)-based NPs [10]. The authors finally analyse that the rationale of developing NPs delivery system is accredited to its better bioavailability and biocompatibility, whereas its pitfall is safety issue.…”